Skip to content
Canli Capital

Research

Pre-Registered Value (composite): a killed candidate

Verdict: KILLED
Test window: 2005-01-04 to 2026-06-01
Identity: prereg_value

Pre-registered composite value on 21 years. Net Sharpe -0.60, failed every gate. Confirms the value thesis does not replicate without small/mid-cap breadth. KILLED.

Why it was worth testing

Value is the oldest documented cross-sectional effect in equities and the one most likely to be already in the price. The question was never whether cheap stocks have outperformed at some point in history; it is whether a mechanical, point-in-time implementation still clears its own trading costs on a universe that includes the companies that went to zero.

The result

Measure Value
Net Sharpe -0.5994
Annualized return -4.05%
Total return -58.75%
Annualized volatility 9.23%
Maximum drawdown -64.27%
Annualized turnover 2.87
Trading days 5385
Final equity (USD) 41,251.08
Fees paid (USD) 292.36

What this does and does not say

It says this configuration, on this data, net of the costs we charge, did not clear the bar it pre-registered. It does not say the underlying economic effect does not exist, that no implementation of it works, or that someone with different data or different execution would reach the same conclusion. A null is evidence about a test, not a proof about a market.

It also does not say the trial was free. Every hypothesis tested raises the deflated-Sharpe hurdle for every sleeve already in the book, including the ones that survived. That is why the kill count is published beside the survivor count rather than behind it.